Updated on 21 January 2014
Phosphagenics will receive an undisclosed royalty from Themis on sales of its Instanac product
Singapore: Novartis launched a topical diclofenac gel, which has been formulated with Australia-based Phosphagenics' proprietary Targeted Penetration Matrix (TPM) drug delivery system, under the product name Voveran TPM gel in India.
Phosphagenics' partner, Themis Medicare, which supplies the diclofenac gel in finished dosage form to Novartis, will shortly launch its own product in the Indian market incorporating TPM under the product name Instanac TPM gel. Phosphagenics will receive an undisclosed royalty from Themis on sales of its Instanac product as well as sales of the Voveran product.
Voveran TPM gel is a prescription pharmaceutical product launched as a line extension to Novartis' Voveran brand (known as Voltaren in many geographic markets). The Novartis product will contain one percent diclofenac (w/w). The product packaging highlights the enhanced delivery provided by Phosphagenics'TPM - Targeted Penetration Matrix - drug delivery system.
Voveran TPM gel is a topical non-steroidal, anti-inflammatory drug indicated for the treatment of pain and inflammation of the muscles and joints caused by osteoarthritis, soft tissue rheumatism and injuries such as sprains and strains.